News
KZIA
5.37
-2.19%
-0.12
Kazia Therapeutics: Buy Rating Maintained Despite Price-Target Cut to $20 on Paxalisib Promise
TipRanks · 12h ago
Kazia Therapeutics Files Fiscal 2026 Annual Report
TipRanks · 17h ago
Kazia Therapeutics Announces Filing of Annual Report on Form 20-F for Fiscal Year Ended June 30, 2026
PR Newswire · 20h ago
Weekly Report: what happened at KZIA last week (1109-1113)?
Weekly Report · 3d ago
Kazia Therapeutics to Host Virtual Event on December 2, 2026: Advancing a New Frontier in Oncology with a First-in-Class Nuclear PD-L1 Protein Degrader
PR Newswire · 11/12 12:00
Weekly Report: what happened at KZIA last week (1102-1106)?
Weekly Report · 11/09 09:07
Kazia Therapeutics Recognized as "Drug Discovery Company of the Year" in 2026 BioTech Breakthrough Awards
PR Newswire · 11/05 12:00
Kazia Therapeutics Delays Annual Filing Amid Controls Review
TipRanks · 11/02 22:41
Kazia Therapeutics Says Two Abstracts Highlighting Paxalisib Tumor And Immune Reprogramming Research Accepted For Poster Presentation At 2026 San Antonio Breast Cancer Symposium
Benzinga · 11/02 12:12
Kazia Therapeutics Announces Two Abstracts on Paxalisib Tumor and Immune Reprogramming Research Accepted for Poster Presentation at 2026 San Antonio Breast Cancer Symposium
PR Newswire · 11/02 12:00
Weekly Report: what happened at KZIA last week (1026-1030)?
Weekly Report · 11/02 09:07
This Kazia Therapeutics Analyst Begins Coverage On A Bullish Note; Here Are Top 4 Initiations For Friday
Benzinga · 10/30 14:28
Reddit downgraded, Rivian upgraded: Wall Street’s top analyst calls
TipRanks · 10/30 13:46
Kazia Therapeutics (KZIA) Receives a Buy from Needham
TipRanks · 10/30 12:07
Kazia Therapeutics Price Target Announced at $27.00/Share by Needham
Dow Jones · 10/30 10:49
Kazia Therapeutics Initiated at Buy by Needham
Dow Jones · 10/30 10:49
Needham Initiates Coverage On Kazia Therapeutics with Buy Rating, Announces Price Target of $27
Benzinga · 10/30 10:39
Kazia Therapeutics to Participate in Fireside Chat at Guggenheim 3rd Annual Healthcare Innovation Conference
PR Newswire · 10/29 11:00
Weekly Report: what happened at KZIA last week (1019-1023)?
Weekly Report · 10/26 09:07
Analysts Are Bullish on These Healthcare Stocks: Abbott Laboratories (ABT), Kazia Therapeutics (KZIA)
TipRanks · 10/22 10:30
More
Webull provides a variety of real-time KZIA stock news. You can receive the latest news about Kazia Therapeuti through multiple platforms. This information may help you make smarter investment decisions.
About KZIA
Kazia Therapeutics Limited is an Australia-based pharmaceutical drug development company. The Company operates in the pharmaceutical research and development business. The Company’s lead program is paxalisib, an investigational brain-penetrant inhibitor of the PI3K / Akt / mTOR pathway, which is being developed to treat multiple forms of brain cancer. It is also developing EVT801, a small-molecule inhibitor of VEGFR3, which is critical to the development of new blood vessels and lymphatic vessels in a growing tumor, as well as to the metastasis of tumors to distant sites in the body. It designed paxalisib to inhibit PI3K, a critical control mechanism in growth and cell division, which is activated in many forms of cancer. The Company’s drug candidates are designed to treat diseases, such as brain cancer, renal cancer, and liver cancer.